Prices are updated after-hours


Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date

t-cell   entities : Tonix pharmaceuticals holding corp.    save search

Tonix Pharmaceuticals Initiates Enrollment in Clinical Trial of TNX-2100, a Diagnostic Skin Test to Measure Functional T Cell Immunity to SARS-CoV-2
Published: 2022-01-11 (Crawled : 13:30) - biospace.com/
SNYNF | News | $92.7 600K twitter stocktwits trandingview |
Health Technology
| | O: -3.41% H: 5.99% C: 1.1%
TNXP | $0.1568 0.9% 900K twitter stocktwits trandingview |
Health Technology
| | O: 0.75% H: 0.0% C: 0.0%
SNY | News | $47.85 1.49% 920K twitter stocktwits trandingview |
Health Technology
| | O: 1.58% H: 0.0% C: 0.0%

sars-cov-2 enroll t-cell diagnostic
Tonix Pharmaceuticals Announces IND Clearance for Skin Test (TNX-2100) to Measure SARS-CoV-2 Exposure and T Cell Immunity
Published: 2021-12-14 (Crawled : 12:30) - globenewswire.com
SNYNF | News | $92.7 600K twitter stocktwits trandingview |
Health Technology
| | O: -3.62% H: 0.0% C: -0.56%
TNXP | $0.1568 0.9% 900K twitter stocktwits trandingview |
Health Technology
| | O: 5.33% H: 0.0% C: 0.0%
SNY | News | $47.85 1.49% 920K twitter stocktwits trandingview |
Health Technology
| | O: -0.51% H: 0.0% C: 0.0%

tnx-2100 als clearance skin cel sars-cov-2 test t-cell
Tonix Pharmaceuticals to Develop COVID-19 Skin Test (TNX-2100) to Measure SARS-CoV-2 Exposure and T Cell Immunity
Published: 2021-02-08 (Crawled : 12:25) - globenewswire.com
TNXP | $0.1568 0.9% 900K twitter stocktwits trandingview |
Health Technology
| | O: 30.63% H: 0.06% C: -6.57%

covid test skin t-cell sars-cov-2
Tonix Pharmaceuticals Enrolls First Patient in COV-LOGIC, an Observational Study to Assess Antibody and T Cell Responses to SARS-CoV-2, the Virus that Causes COVID-19
Published: 2020-09-15 (Crawled : 13:59) - globenewswire.com
TNXP | $0.1568 0.9% 900K twitter stocktwits trandingview |
Health Technology
| | O: 7.81% H: 4.82% C: -3.54%

covid antibody t-cell sars-cov-2 enroll
Tonix Pharmaceuticals to Host Live Webinar: Antibody vs. T Cell Immunity: Is a Single Vaccine Enough to Stop COVID-19?
Published: 2020-09-17 (Crawled : 13:59) - globenewswire.com
TNXP | $0.1568 0.9% 900K twitter stocktwits trandingview |
Health Technology
| | O: 1.34% H: 21.32% C: 11.21%

covid vaccine antibody t-cell
Gainers vs Losers
87% 13%

Top 10 Gainers
MTTR | News M | $4.64 166.67% 18M twitter stocktwits trandingview |

AGBA | $2.61 108.8% 41M twitter stocktwits trandingview |
Finance

CZOO | $9.32 86.77% 18M twitter stocktwits trandingview |

EDBL | News | $6.7 78.19% 1.7M twitter stocktwits trandingview |

OPRT | News | $3.37 49.78% 8.9M twitter stocktwits trandingview |
Finance

MTC | $2.14 37.18% 4.9M twitter stocktwits trandingview |
Technology Services

VNRX | $0.8 33.33% 2.9M twitter stocktwits trandingview |
Health Technology

MLEC | $1.79 27.86% 2.6M twitter stocktwits trandingview |
n/a

PALI | $6.29 27.59% 22M twitter stocktwits trandingview |
Manufacturing

MCRB | $0.7902 26.51% 6.9M twitter stocktwits trandingview |
Health Technology


Your saved searches
Save your searches and get alerts when important news are released.